540
staff
Esther Krofah
Esther Krofah is the executive vice president of MI Health, leading FasterCures, Public Health, t
he Future of Aging, and Feeding Change.
+ Read More
staff
Anna Lin-Schweitzer
Anna Lin-Schweitzer is a senior associate with Feeding Change at the Milken Institute.
staff
Erika Stratmann
Erika Stratmann is the Director of Communications, Health. She is a mission-driven communica
tions and content development leader with more than a decade of experience advancing consumer education, community engagement and advocacy campaigns.
+ Read More
staff
Ilana Moreno
Ilana Moreno is a Senior Associate with Feeding Change at the Milken Institute.
staff
Holly Freishtat
Holly Freishtat is the senior director of Feeding Change at the Milken Institute.
report
Strengthening the Biomedical Innovation Ecosystem: A Scorecard for System Assessment
As patients, we often evaluate our interactions within the "system" of biomedical innovation with a
simple question: "Did it work for me?" This evaluation considers many issues, including whether the best treatments are accessible and available, how the
+ Read More
report
Cell and Gene Therapies: Looking Ahead to 2022
Cell and gene therapies are a new category of medicines transforming how we treat and potentially c
ure disease. Both cell and gene therapies seek to modify genetic material to fight disease.
+ Read More
report
COVID-19 Silver Linings for Biomedical Innovation: Implementation Roadmap
While the response to the COVID-19 pandemic has exposed many of the fault lines in the biomedical i
nnovation ecosystem that have slowed progress for decades, we have also shown ourselves capable of innovating in ways we perhaps did not think possible.
+ Read More
report
The Promise of Multi-Cancer Early Detection Technologies in Encouraging Research and Development
New blood-based technologies, known as multi-cancer early detection (MCED) tests, are entering 
;the market and can identify multiple cancers early and simultaneously.
+ Read More
report
Creating a Nonprofit Marketplace for Shelved Drugs: Lessons from a Pilot Project
Many promising medicines, despite strong safety data and pharmaceutical characteristics, are discon
tinued by drug companies for nonscientific reasons, including strategic, organizational, and financial considerations.
+ Read More
report
Supporting the Growth of California's Life Sciences Industry
The life sciences are a cornerstone of technological innovation in California.
report
Envisioning a Trusted System for Health Data Accelerating Medical Research
Technological innovation in the health landscape is occurring rapidly, and much of it would not be
possible without patient data.
+ Read More